COVID-19 Clinical Trial Pipeline Advances With 180+ Companies and 200+ Therapies

Ibuzatrelvir (PF-07817883), developed by Pfizer, is an investigational oral SARS-CoV-2 main protease inhibitor. It is designed to work without ritonavir boosting, potentially simplifying treatment and reducing certain drug-drug interaction concerns. The therapy is currently being evaluated in Phase III development.

N-803, developed by ImmunityBio, Inc., is an interleukin-15 superagonist fusion protein designed to stimulate natural killer and CD8+ T-cell responses. It is currently being investigated in Phase II development for COVID-19.

ENTVAX002, also known as Covigenix VAX-002, is an investigational plasmid DNA vaccine developed by Entos Pharmaceuticals Inc. in partnership with Aegis Life. The vaccine is designed to address emerging SARS-CoV-2 variants and is currently in Phase II development.

ALG-097558, developed by Aligos Therapeutics, is a ritonavir-free pan-coronavirus protease inhibitor. Preclinical research has demonstrated activity against multiple SARS-CoV-2 variants, as well as broader coronavirus targets. The candidate is currently being evaluated in Phase II development.

RBM001, MDX2301, and PA-001 represent additional early-stage approaches. RBM001 is a protein-based vaccine designed to target conserved regions of the viral spike protein, while MDX2301 is a multispecific antibody intended to neutralize diverse SARS-CoV-2 variants. PA-001 is a peptide-based inhibitor targeting the S2 domain of the spike protein and is being evaluated in Phase I development.

Explore groundbreaking therapies and clinical trials in the COVID-19 Pipeline @ New COVID-19 Drugs - https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

COVID-19 Pipeline Assessment and Development Landscape

The COVID-19 Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The COVID-19 Pipeline Report also highlights the unmet needs with respect to the COVID-19.

The report evaluates companies developing COVID-19 therapies and provides an assessment of their respective pipeline assets. It examines therapeutic candidates across early-, mid-, and late-stage development and identifies active, dormant, and discontinued projects.

The analysis also categorizes COVID-19 drugs according to clinical development stage, route of administration, target receptor, mechanism of action, molecular type, and use as monotherapy or combination therapy. In addition, the report examines company-company and company-academia collaborations, licensing agreements, and financing activities supporting future development.

Learn about new COVID-19 drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ COVID-19 Market Drivers and Barriers - https://www.delveinsight.com/report-store/covid-19-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Scope of the COVID-19 Pipeline Report